Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway

Molecular Cancer Therapeutics

Volumn 13, Issue 5, 2014, Pages 1078-1091

  Yu, Peiwen ^a   Laird, A Douglas ^a   Du, Xiangnan ^a   Wu, Jianming ^a   Won, Kwang Ai ^a   Yamaguchi, Kyoko ^a   Hsu, Pin Pin ^a   Qian, Fawn ^a   Jaeger, Christopher T ^a   Zhang, Wentao ^a   Buhr, Chris A ^a   Shen, Paula ^a   Abulafia, Wendy ^a   Chen, Jason ^a   Young, Jenny ^a   Plonowski, Arthur ^a   Yakes, F Michael ^a   Chu, Felix ^a   Lee, Michelle ^a   Bentzien, Frauke ^a   Lam, Sanh Tan ^a   Dale, Stephanie ^a   Matthews, David J ^a   Lamb, Peter ^a   Foster, Paul ^a   more..

^a EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CYCLIN D1; P70S6K PROTEIN; PROTEIN; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 DELTA; PROTEIN P110BETA; PROTEIN P110GAMMA; PROTEIN S6; SAR 245409; UNCLASSIFIED DRUG; XL 765; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; POLYPHOSPHOINOSITIDE; PROTEIN KINASE INHIBITOR; QUINOXALINE DERIVATIVE; S6 KINASE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE; VOXTALISIB;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; IC50; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SULFONAMIDES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899711229     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0709     Document Type: Article

References (36)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
2. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008;27:5486-96.
3. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstreamofGprotein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008;105: 8292-7.
4. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 1997;89:457-67.
5. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010;7:209-19.
6. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
7. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument- Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-302.
8. Febuary 2014 search of COSMIC database. Available from: http:// www. sanger. ac. uk/genetics/CGP/cosmic/.
9. Hollander MC, BlumenthalGM,Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
10. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1/ AMPK/TSC/mTORC1 signaling. Oncogene 2011;30:2289-303.
11. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
12. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci U S A 2008;105:9739-44.
13. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008;68:6598-607.
14. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010;16:4325-30.
15. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther 2009; 8:21-6.
16. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-502.
17. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009;106: 19503-8.
18. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011;71:1081-91.
19. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Breast Cancer Special feature: feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A 2012;109:2718-23.
20. Klein S, Levitzki A. Targeting the EGFRand the PKB pathway in cancer. Curr Opin Cell Biol 2009;21:185-93.
21. Priulla M, Calastretti A, Bruno P, Azzariti A, Paradiso A, Canti G, et al. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate 2007;67:782-9.
22. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011;17: 2373-84.
23. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
24. García-Echeverría C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010;20: 4308-12.
25. Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, et al. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res 2007;13: 3713-23.
26. Bussenius J, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, et al. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors. Bioorg Med Chem Lett 2012;22:2283-6.
27. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.
28. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56.
29. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 2005;65:7800-8.
30. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-9.
31. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009;21:199-208.
32. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 30 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16:3670-83.
33. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011;17: 3272-81.
34. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/ AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013;73:276-84.
35. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011;13: 384-92.
36. Cloughesy TF, Mischel PS, Omuro AMP, Prados M, Wen PY, Wu B, et al. Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): an Ivy foundation early-phase clinical trials consortium study. J Clin Oncol 2013;31 (suppl; abstr 2012).